DK0954588T3 - OB fusionsprotein-sammensætninger og fremgangsmåder - Google Patents

OB fusionsprotein-sammensætninger og fremgangsmåder

Info

Publication number: DK0954588T3
Authority: DK; Denmark
Prior art keywords: methods; fusion protein; protein compositions; compositions; fusion
Prior art date: 1996-12-20

Application number

DK97952464T

Other languages

English (en)

Inventor

Michael Benjamin Mann

Randy Ira Hecht

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-20

Filing date

1997-12-11

Publication date

2007-05-14

1997-12-11 Application filed by Amgen Inc filed Critical Amgen Inc

2007-05-14 Application granted granted Critical

2007-05-14 Publication of DK0954588T3 publication Critical patent/DK0954588T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Plant Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Child & Adolescent Psychology (AREA)
Physics & Mathematics (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Gastroenterology & Hepatology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)

DK97952464T 1996-12-20 1997-12-11 OB fusionsprotein-sammensætninger og fremgangsmåder DK0954588T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US77097396A	1996-12-20	1996-12-20
PCT/US1997/023183 WO1998028427A1 (en)	1996-12-20	1997-12-11	Ob fusion protein compositions and methods

Publications (1)

Publication Number	Publication Date
DK0954588T3 true DK0954588T3 (da)	2007-05-14

Family

ID=25090296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97952464T DK0954588T3 (da)	1996-12-20	1997-12-11	OB fusionsprotein-sammensætninger og fremgangsmåder

Country Status (25)

Country	Link
EP (2)	EP1835030A1 (da)
JP (2)	JP4175668B2 (da)
KR (1)	KR100937550B1 (da)
CN (1)	CN1195858C (da)
AR (2)	AR009436A1 (da)
AT (1)	ATE351910T1 (da)
AU (1)	AU5606098A (da)
BG (1)	BG64288B1 (da)
BR (1)	BR9713755A (da)
CA (1)	CA2275183A1 (da)
CZ (1)	CZ298203B6 (da)
DE (1)	DE69737266T2 (da)
DK (1)	DK0954588T3 (da)
EA (2)	EA004790B1 (da)
ES (1)	ES2280083T3 (da)
HU (1)	HU227088B1 (da)
IL (1)	IL130396A (da)
NO (2)	NO324506B1 (da)
NZ (1)	NZ514145A (da)
PL (1)	PL194159B1 (da)
PT (1)	PT954588E (da)
RS (1)	RS49927B (da)
SK (1)	SK287578B6 (da)
WO (1)	WO1998028427A1 (da)
ZA (1)	ZA9711239B (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6936439B2 (en)	1995-11-22	2005-08-30	Amgen Inc.	OB fusion protein compositions and methods
ES2217327T3 (es) *	1995-11-22	2004-11-01	Amgen Inc.,	Proteina ob para aumentar la masa de tejido magro.
US20030040467A1 (en)	1998-06-15	2003-02-27	Mary Ann Pelleymounter	Ig/ob fusions and uses thereof.
US6620413B1 (en)	1995-12-27	2003-09-16	Genentech, Inc.	OB protein-polymer chimeras
US6541604B1 (en)	1996-01-08	2003-04-01	Genentech, Inc.	Leptin receptor having a WSX motif
US20050019325A1 (en)	1996-01-08	2005-01-27	Carter Paul J.	WSX receptor agonist antibodies
US7074397B1 (en)	1996-01-08	2006-07-11	Genentech, Inc.	Method for enhancing proliferation or differentiation of a cell using ob protein
ATE223229T1 (de) *	1997-04-17	2002-09-15	Amgen Inc	Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
US20020019352A1 (en) *	1997-04-17	2002-02-14	David N. Brems	Stable, active, human ob protein compositions and methods
ES2590912T3 (es)	1997-12-08	2016-11-24	Merck Patent Gmbh	Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
EP1950224A3 (en)	1998-03-09	2008-12-17	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en)	1998-10-14	2002-07-16	Amgen Inc.	Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US7488590B2 (en)	1998-10-23	2009-02-10	Amgen Inc.	Modified peptides as therapeutic agents
DK1783222T3 (da)	1998-10-23	2012-07-09	Kirin Amgen Inc	Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
US6660843B1 (en)	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US8106098B2 (en)	1999-08-09	2012-01-31	The General Hospital Corporation	Protein conjugates with a water-soluble biocompatible, biodegradable polymer
AU778611B2 (en)	1999-08-09	2004-12-16	Merck Patent Gmbh	Multiple cytokine-antibody complexes
CA2391080A1 (en)	1999-11-12	2001-05-25	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Erythropoietin forms with improved properties
US6808902B1 (en)	1999-11-12	2004-10-26	Amgen Inc.	Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
ATE336514T1 (de)	2000-02-11	2006-09-15	Merck Patent Gmbh	Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US20020168363A1 (en) *	2000-04-21	2002-11-14	Amgen Inc.	Integrin/adhesion antagonists
US6677136B2 (en) *	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
US20020090646A1 (en) *	2000-05-03	2002-07-11	Amgen Inc.	Calcitonin-related molecules
ATE368475T1 (de)	2000-06-29	2007-08-15	Emd Lexigen Res Ct Corp	Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
EP1366455B1 (en)	2001-02-19	2008-07-02	MERCK PATENT GmbH	Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
BR0207854A (pt)	2001-03-07	2004-08-24	Merck Patent Gmbh	Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
WO2002079415A2 (en)	2001-03-30	2002-10-10	Lexigen Pharmaceuticals Corp.	Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) *	2001-04-11	2002-10-22	Chemo Sero Therapeut Res Inst	大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
DK1383785T3 (da)	2001-05-03	2011-05-23	Merck Patent Gmbh	Rekombinant tumorspecifikt antistof og anvendelse deraf
PL214862B1 (pl)	2001-10-22	2013-09-30	Amgen	Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
PT1454138E (pt)	2001-12-04	2012-03-28	Merck Patent Gmbh	Imunocitoquinas com seletividade modulada
NZ534757A (en)	2002-03-12	2006-07-28	Merck & Co Inc	Substituted amides
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
DK1572748T3 (da)	2002-12-17	2010-08-23	Merck Patent Gmbh	Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
JP3936673B2 (ja) *	2003-06-02	2007-06-27	国立大学法人群馬大学	Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
ES2305886T3 (es)	2003-12-30	2008-11-01	Merck Patent Gmbh	Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
US8420087B2 (en)	2004-01-05	2013-04-16	Antisoma Research Limited	Interleukin-12 targeted to oncofoetal fibronectin
US8603969B2 (en)	2004-02-11	2013-12-10	Amylin Pharmaceuticals, Llc	Pancreatic polypeptide family motifs and polypeptides comprising the same
US8076288B2 (en)	2004-02-11	2011-12-13	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides having glucose lowering activity
JP2008505928A (ja)	2004-07-08	2008-02-28	アムジェン　インコーポレーテッド	治療用ペプチド
DK2412728T3 (da)	2004-08-03	2015-04-07	Innate Pharma	Terapeutiske præparater mod cancer, der er rettet mod 4Ig-B7-H3
WO2006036834A2 (en)	2004-09-24	2006-04-06	Amgen Inc.	MODIFIED Fc MOLECULES
ES2325773T5 (es)	2004-11-01	2014-02-24	Amylin Pharmaceuticals, Llc.	Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en)	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
JP4937132B2 (ja)	2004-12-09	2012-05-23	メルクパテントゲゼルシャフトミットベシュレンクテルハフツング	免疫原性の低下したｉｌ−７変種
JP2009504681A (ja) *	2005-08-11	2009-02-05	アミリン・ファーマシューティカルズ，インコーポレイテッド	選択可能な特性を有するハイブリッドポリペプチド
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
JP4860702B2 (ja)	2005-10-21	2012-01-25	エフ．ホフマン−ラロシュアーゲー	ポリペプチドのリコンビナント発現のための方法
DOP2007000020A (es)	2006-01-31	2007-09-15	Bayer Schering Pharma Ag	Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
US8501686B2 (en)	2008-06-05	2013-08-06	University Of Michigan	Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
MX2011011044A (es)	2009-04-22	2011-11-04	Merck Patent Gmbh	Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
NZ714757A (en)	2009-08-14	2018-07-27	Us Gov Health & Human Services	Use of il-15 to increase thymic output and to treat lymphopenia
EA024507B1 (ru)	2010-09-28	2016-09-30	Амилин Фармасьютикалс, Ллк	Хорошо растворимые лептины
DK2729160T3 (da)	2011-07-08	2019-07-01	Aegerion Pharmaceuticals Inc	Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
WO2013052456A1 (en)	2011-10-05	2013-04-11	Nanosys, Inc.	Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
EP3434268B1 (en)	2012-09-27	2022-04-20	The Children's Medical Center Corporation	Compounds for the treatment of obesity and methods of use thereof
TR201901299T4 (tr)	2013-11-26	2019-02-21	Childrens Medical Ct Corp	Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
WO2015153933A1 (en)	2014-04-03	2015-10-08	The Children's Medical Center Corporation	Hsp90 inhibitors for the treatment of obesity and methods of use thereof
EP3509624B1 (en)	2016-09-12	2023-08-09	Amryt Pharmaceuticals Inc.	Methods of detecting anti-leptin neutralizing antibodies
CN110396133B (zh)	2018-04-25	2021-07-23	免疫靶向有限公司	一种以白介素12为活性成分的融合蛋白型药物前体
CN110183530A (zh) *	2019-06-21	2019-08-30	深圳市亚辉龙生物科技股份有限公司	瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) *	2019-10-08	2021-10-08	北京东方百泰生物科技股份有限公司	一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
AU3382595A (en) *	1994-07-29	1996-03-04	Smithkline Beecham Corporation	Novel compounds
US6309853B1 (en) *	1994-08-17	2001-10-30	The Rockfeller University	Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) *	1994-09-05	1996-03-19	Tosoh Corp	組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) *	1995-06-13	1995-08-09	Smithkline Beecham Plc	Novel compound
ES2217327T3 (es) *	1995-11-22	2004-11-01	Amgen Inc.,	Proteina ob para aumentar la masa de tejido magro.
JP4037905B2 (ja) *	1995-12-27	2008-01-23	ジェネンテック・インコーポレーテッド	半減期の長いｏｂタンパク質誘導体

1997
- 1997-12-11 EA EA199900575A patent/EA004790B1/ru not_active IP Right Cessation
- 1997-12-11 EA EA200100216A patent/EA004791B1/ru not_active IP Right Cessation
- 1997-12-11 CA CA002275183A patent/CA2275183A1/en not_active Abandoned
- 1997-12-11 DE DE69737266T patent/DE69737266T2/de not_active Expired - Lifetime
- 1997-12-11 EP EP06024946A patent/EP1835030A1/en not_active Withdrawn
- 1997-12-11 KR KR1019997005618A patent/KR100937550B1/ko not_active Expired - Fee Related
- 1997-12-11 CN CNB971818177A patent/CN1195858C/zh not_active Expired - Fee Related
- 1997-12-11 NZ NZ514145A patent/NZ514145A/en not_active IP Right Cessation
- 1997-12-11 CZ CZ0203699A patent/CZ298203B6/cs not_active IP Right Cessation
- 1997-12-11 PT PT97952464T patent/PT954588E/pt unknown
- 1997-12-11 IL IL130396A patent/IL130396A/en not_active IP Right Cessation
- 1997-12-11 DK DK97952464T patent/DK0954588T3/da active
- 1997-12-11 WO PCT/US1997/023183 patent/WO1998028427A1/en not_active Ceased
- 1997-12-11 JP JP52889698A patent/JP4175668B2/ja not_active Expired - Fee Related
- 1997-12-11 EP EP97952464A patent/EP0954588B1/en not_active Expired - Lifetime
- 1997-12-11 PL PL334242A patent/PL194159B1/pl not_active IP Right Cessation
- 1997-12-11 RS YUP-279/99A patent/RS49927B/sr unknown
- 1997-12-11 SK SK774-99A patent/SK287578B6/sk not_active IP Right Cessation
- 1997-12-11 AU AU56060/98A patent/AU5606098A/en not_active Abandoned
- 1997-12-11 BR BR9713755-3A patent/BR9713755A/pt active Search and Examination
- 1997-12-11 AT AT97952464T patent/ATE351910T1/de active
- 1997-12-11 HU HU0000302A patent/HU227088B1/hu not_active IP Right Cessation
- 1997-12-11 ES ES97952464T patent/ES2280083T3/es not_active Expired - Lifetime
- 1997-12-15 ZA ZA9711239A patent/ZA9711239B/xx unknown
- 1997-12-16 AR ARP970105894A patent/AR009436A1/es active IP Right Grant
1999
- 1999-06-08 NO NO19992779A patent/NO324506B1/no not_active IP Right Cessation
- 1999-06-23 BG BG103522A patent/BG64288B1/bg unknown
2007
- 2007-03-16 NO NO20071415A patent/NO325096B1/no not_active IP Right Cessation
- 2007-03-16 AR ARP070101065A patent/AR059907A2/es unknown
2008
- 2008-05-29 JP JP2008140707A patent/JP4659068B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BG64288B1 (bg)	2004-08-31
CZ298203B6 (cs)	2007-07-18
JP4659068B2 (ja)	2011-03-30
JP2001512417A (ja)	2001-08-21
EA004790B1 (ru)	2004-08-26
EP0954588A1 (en)	1999-11-10
HUP0000302A3 (en)	2005-12-28
NO992779L (no)	1999-08-19
RS49927B (sr)	2008-09-29
AU5606098A (en)	1998-07-17
PL334242A1 (en)	2000-02-14
PL194159B1 (pl)	2007-05-31
DE69737266D1 (de)	2007-03-08
CN1246154A (zh)	2000-03-01
JP4175668B2 (ja)	2008-11-05
YU27999A (sh)	2000-10-30
WO1998028427A1 (en)	1998-07-02
CZ9902036A3 (cs)	2000-10-11
ZA9711239B (en)	1998-06-23
HU227088B1 (en)	2010-06-28
IL130396A (en)	2011-09-27
EA199900575A1 (ru)	2000-02-28
BG103522A (en)	2000-03-31
DE69737266T2 (de)	2007-11-08
EP1835030A1 (en)	2007-09-19
KR20000069617A (ko)	2000-11-25
NZ514145A (en)	2003-08-29
NO20071415L (no)	1999-08-19
SK287578B6 (sk)	2011-03-04
CA2275183A1 (en)	1998-07-02
NO324506B1 (no)	2007-11-05
IL130396A0 (en)	2000-06-01
AR059907A2 (es)	2008-05-07
EA004791B1 (ru)	2004-08-26
KR100937550B1 (ko)	2010-01-19
SK77499A3 (en)	2001-04-09
ES2280083T3 (es)	2007-09-01
EP0954588B1 (en)	2007-01-17
CN1195858C (zh)	2005-04-06
HK1021388A1 (en)	2000-06-09
EA200100216A1 (ru)	2001-08-27
BR9713755A (pt)	2000-02-01
ATE351910T1 (de)	2007-02-15
AR009436A1 (es)	2000-04-12
JP2008289487A (ja)	2008-12-04
NO325096B1 (no)	2008-02-04
NO992779D0 (no)	1999-06-08
HUP0000302A2 (hu)	2000-06-28
PT954588E (pt)	2007-03-30

Publication	Publication Date	Title
DK0954588T3 (da)	2007-05-14	OB fusionsprotein-sammensætninger og fremgangsmåder
NO991676D0 (no)	1999-04-09	FremgangsmÕter og sammensetninger for immunmodulering
NO973046D0 (no)	1997-06-30	Elastiske sementsammensetninger og fremgangsmåte
NO973048D0 (no)	1997-06-30	Elastiske sementsammensetninger og fremgangsmåter
NO20000700D0 (no)	2000-02-11	Interleukin-18-proteiner samt fremstilling og anvendelse derav
IS1810B (is)	2002-04-30	Úðablöndur úr peptíðum og próteinum
NO963371D0 (no)	1996-08-13	Hematopoeseprotein samt materialer og fremgangsmåter for fremstilling av det
ZA964733B (en)	1997-01-07	Ob protein compositions and methods
DK0915880T3 (da)	2008-02-11	Azolotriaziner og pyrimidiner
BR9709529A (pt)	1999-08-10	Fragmentos de leptina (proteína ob)
DK0804078T3 (da)	2000-04-10	Sammensætning og anvendelse deraf
NO985385D0 (no)	1998-11-19	Bitumensammensetninger og fremgangsmÕte for fremstilling derav
NO982181D0 (no)	1998-05-13	Type IX collagen og chimerer
NO971505D0 (no)	1997-04-03	Trofinin og trofininhjelperproteiner
NO985806L (no)	1999-02-11	Kitinasematerialer og fremgangsmÕter
NO995062D0 (no)	1999-10-15	<Beta>-anyloidpeptid-bindende proteiner og polynuldeotider som kodes for samme
TR199701666A3 (tr)	1999-10-21	Sismanliga karsi proteinler
HUP0000280A3 (en)	2002-09-30	Canine ob protein compositions and methods
NO973047D0 (no)	1997-06-30	Elastiske sementsammensetninger og fremgangsmåter
NO20005547D0 (no)	2000-11-03	Myelinbasiske proteinpeptider og anvendelser derav
NO983556D0 (no)	1998-08-03	Formulering og anvendelse
DE59704868D1 (de)	2001-11-15	Gelenk
DE59712815D1 (de)	2007-03-29	Aussenspiegelgelenk
NO952766L (no)	1996-01-19	Opplösningsmiddelsammensetninger og metoder
SE9602287D0 (sv)	1996-06-10	Novel protein and methods for its use